Immuno-oncology 2025 & Beyond: Where Innovation Meets Market Leadership
Industry Imperative
Industry Imperative By 2050, global cancer incidence will surpass 35 million new cases annually – a 77% surge from 2022. The immuno-oncology (I-O) therapeutics market is leading the fight, but challenges in trial design, patient selection, and therapy resistance demand new strategies and disruptive technologies.
What This Analysis Covers
Our comprehensive analysis delivers:
-
2025–2030 global I-O revenue streams
-
Competitive benchmarking of Merck, Roche, Bristol Myers Squibb, J&J, and more
-
Emerging therapeutic categories: CAR-T, TCR, bispecifics, cancer vaccines
-
AI-driven clinical trial innovations
-
Biomarker advancements: multiplex IHC, NGS, metabolic profiling
-
Strategic growth areas: multi-biomarker approaches & neoadjuvant immunotherapy
And more….
Access the Full Analysis Now
Why This Matters Now
With 88.5% of market revenue controlled by the top 10 players, competition is fierce. The winners will be those who align early with next-gen I-O targets, combination therapies, adaptive trial designs, and global collaboration models to close cancer care disparities.
Gain the intelligence to make high-ROI decisions in one of the most competitive and fast-growing healthcare markets.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on store.frost.com.
*$1,000 honorarium is subject to eligibility
